Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Neurogene Inc.AQXP · Entity 5160 | Director | May 07, 2018 | May 09, 2018 |
| X4 Pharmaceuticals, IncXFOR · Entity 5638 | Director | January 01, 2026 | January 07, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Neurogene Inc.
Report date May 07, 2018 · Filed May 09, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.10 · Expires 2028-05-06 | Direct | 15,000 |
Reported balance
After 2018-05-07 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-05-07 · Grant · Acquired 15,000 · Balance 15,000 F1: The shares subject to this option shall vest and become exercisable at a rate of 1/12th of the total number of shares underlying the options on the one-month anniversary of May 7, 2018 (the "Vesting Commencement Date") and 1/12th of the total number of shares underlying the options each monthly anniversary of the Vesting Commencement Date thereafter for so long as the recipient of the option provides continuous service to the issuer, such that the total number of shares underlying the options shall be fully vested on the one-year anniversary of the Vesting Commencement Date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to this option shall vest and become exercisable at a rate of 1/12th of the total number of shares underlying the options on the one-month anniversary of May 7, 2018 (the "Vesting Commencement Date") and 1/12th of the total number of shares underlying the options each monthly anniversary of the Vesting Commencement Date thereafter for so long as the recipient of the option provides continuous service to the issuer, such that the total number of shares underlying the options shall be fully vested on the one-year anniversary of the Vesting Commencement Date.
X4 Pharmaceuticals, Inc
Report date January 01, 2026 · Filed January 07, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.00 · Expires 2036-01-01 | Direct | 0 |
Reported balance
After 2026-01-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-01-01 · Grant · Acquired 110,000 · Balance 0 F1: The shares subject to the option shall vest in full upon stockholder approval of an increase in the share reserve under the Companys Amended and Restated 2017 Equity Incentive Plan at the Companys 2026 annual meeting of stockholders, subject to the Reporting Person continuing to provide services through such date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option shall vest in full upon stockholder approval of an increase in the share reserve under the Companys Amended and Restated 2017 Equity Incentive Plan at the Companys 2026 annual meeting of stockholders, subject to the Reporting Person continuing to provide services through such date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 01, 2026 Filed Jan 7, 2026 21:00 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | GrantStock Option (right to buy) · Derivative | 110,000 | $0.00 Strike: $4.00 | $0.00 |
DisclosureSEC source: 0001501697-26-000009 · wk-form4_1767819605.xml · derivative · entry 1 Bridger Gary · CIK 0001600049 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 110,000 shares Expires 2036-01-01 F1 · derivative.exercise_date: The shares subject to the option shall vest in full upon stockholder approval of an increase in the share reserve under the Companys Amended and Restated 2017 Equity Incentive Plan at the Companys 2026 annual meeting of stockholders, subject to the Reporting Person continuing to provide services through such date. Read SEC document |
| June 09, 2025 Filed Jun 10, 2025 20:30 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | GrantCommon Stock | 1,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-030502 · wk-form4_1749587426.xml · nonDerivative · entry 1 Bridger Gary · CIK 0001600049 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,722 F1 · shares: Represents restricted stock units (RSUs) granted to the Reporting Person as an annual award for service on the Board of Directors. The RSUs will vest in full on the earlier of (i) the one-year anniversary of the grant date or (ii) the Issuer's next annual meeting of stockholders, subject to continued board service through the applicable vesting date. The RSUs will vest in full upon the occurrence of a change in control of the Issuer. Read SEC document |
| June 10, 2024 Filed Jun 11, 2024 20:12 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | GrantCommon Stock | 45,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-24-027674 · wk-form4_1718136760.xml · nonDerivative · entry 1 Bridger Gary · CIK 0001600049 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 96,667 F1 · shares: Represents restricted stock units (RSUs) granted to the Reporting Person as an annual award for service on the Board of Directors. The RSUs will vest in full on the earlier of (i) the one-year anniversary of the grant date or (ii) the Issuer's next annual meeting of stockholders, subject to continued board service through the applicable vesting date. The RSUs will vest in full upon the occurrence of a change in control of the Issuer. Read SEC document |
| June 13, 2023 Filed Jun 14, 2023 21:05 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | GrantCommon Stock | 45,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-23-022096 · wk-form4_1686776741.xml · nonDerivative · entry 1 Bridger Gary · CIK 0001600049 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,667 F1 · shares: Represents restricted stock units (?RSUs?) granted to the Reporting Person as an annual award for service on the Board of Directors. The RSUs will vest in full on the earlier of (i) the one-year anniversary of the grant date or (ii) the Issuer?s next annual meeting of stockholders, subject to continued board service through the applicable vesting date. The RSUs will vest in full upon the occurrence of a change in control of the Issuer. Read SEC document |
| June 06, 2022 Filed Jun 27, 2022 20:17 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | GrantCommon Stock | 6,667 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-22-018055 · wf-form4_165636102734162.xml · nonDerivative · entry 1 Bridger Gary · CIK 0001600049 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,667 F1 · shares: Represents an annual grant of restricted stock units ("RSUs") for service as a director to the Issuer. The RSUs will vest in two equal annual installments on June 6, 2023 and June 6, 2024, subject to the Reporting Person continuing to provide service to the Issuer through the applicable vesting date. F2 · balance_after: Represents unvested RSUs. Read SEC document |
| June 02, 2021 Filed Jun 2, 2021 21:04 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | GrantStock Option (right to buy) · Derivative | 6,000 | $9.50 Strike: $9.50 | $57,000.00 |
DisclosureSEC source: 0001628280-21-011547 · wf-form4_162266783712804.xml · derivative · entry 1 Bridger Gary · CIK 0001600049 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 6,000 shares Expires 2031-06-02 F1 · derivative.exercise_date: 8.3333% of the shares subject to the option shall vest on July 2, 2021, with the remainder vesting in equal monthly installments of 8.333% of the shares subject to the option until the 12-month anniversary of the date of the grant (or, if earlier, the date of the Issuer's next annual meeting of stockholders following the date of the grant) subject to the Reporting Person continuing to provide services through each such date. Read SEC document |
| October 05, 2020 Filed Oct 6, 2020 11:36 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | GrantStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $7.33 | $0.00 |
DisclosureSEC source: 0001628280-20-014320 · wf-form4_160198417729837.xml · derivative · entry 1 Bridger Gary · CIK 0001600049 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2030-10-04 F1 · derivative.exercise_date: 33.3333% of the shares subject to the option shall vest on October 5, 2021, with the remainder vesting in equal monthly installments of 2.7777% of the shares subject to the option until the 36-month anniversary of the date of the grant, subject to the Reporting Person's continued services as a director through each applicable vesting date. Read SEC document |
| June 10, 2020 Filed Jun 11, 2020 12:22 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | GrantStock Option (right to buy) · Derivative | 3,427 | $0.00 Strike: $8.69 | $0.00 |
DisclosureSEC source: 0001628280-20-009230 · wf-form4_159187812734850.xml · derivative · entry 1 Bridger Gary · CIK 0001600049 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,427 Underlying: Common Stock · 3,427 shares Expires 2030-06-09 F1 · derivative.exercise_date: 8.3333% of the shares subject to the option shall vest on July 10, 2020, with the remainder vesting in equal monthly installments of 8.333% of the shares subject to the option until the 12-month anniversary of the date of the grant (or, if earlier, the date of the Issuer's next annual meeting of stockholders following the date of the grant) subject to the Reporting Person continuing to provide services through each such date. Read SEC document |
| March 13, 2019 Filed Mar 15, 2019 01:38 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | GrantStock Option (right to buy) · Derivative | 21,570 | Not disclosed Strike: $10.44 | Not disclosed |
DisclosureSEC source: 0000899243-19-007832 · doc4.xml · derivative · entry 1 Bridger Gary · CIK 0001600049 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,570 Underlying: Common Stock · 21,570 shares Expires 2028-10-03 F2 · price: Reflects the Reporting Person's stock option to acquire 226,983 shares of X4 common stock for $0.99 per share that was assumed by the Issuer in the merger of Artemis AC Corp., a wholly-owned subsidiary of the Issuer, with and into X4 Therapeutics, Inc. (formerly X4 Pharmaceuticals, Inc.) ("X4") on March 13, 2019 (the "Merger"). F1 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to the option vested on October 4, 2019, and one thirty-sixth (1/36th) of the shares subject to the option shall vest each month thereafter, subject to the Reporting Person continuing to provide service through each such date. Read SEC document |
| March 13, 2019 Filed Apr 3, 2019 00:04 UTC Amendment | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | GrantStock Option (right to buy) · Derivative | 6,854 | $0.00 Strike: $18.66 | $0.00 |
DisclosureSEC source: 0000899243-19-009671 · doc4a.xml · derivative · entry 2 Bridger Gary · CIK 0001600049 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,854 Underlying: Common Stock · 6,854 shares Expires 2029-03-13 F3 · derivative.exercise_date: 33.3333% of the shares subject to the option shall vest on March 13, 2020, with the remainder vesting in equal monthly installments of 2.7777% of the shares subject to the option until the 36-month anniversary of the date of the award, subject to the Reporting Person continuing to provide service through each such date. This amendment is being filed solely to report this additional stock option grant, which was granted automatically on March 13, 2019 pursuant to the Issuer's Director Compensation Policy upon such Reporting Person's election to the Board of Directors of the Issuer in connection with the closing of the Merger. Read SEC document |
| March 13, 2019 Filed Apr 3, 2019 00:04 UTC Amendment | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | GrantStock Option (right to buy) · Derivative | 21,570 | Not disclosed Strike: $10.44 | Not disclosed |
DisclosureSEC source: 0000899243-19-009671 · doc4a.xml · derivative · entry 1 Bridger Gary · CIK 0001600049 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,570 Underlying: Common Stock · 21,570 shares Expires 2028-10-03 F2 · price: Reflects the Reporting Person's stock option to acquire 226,983 shares of X4 common stock for $0.99 per share that was assumed by the Issuer in the merger of Artemis AC Corp., a wholly-owned subsidiary of the Issuer, with and into X4 Therapeutics, Inc. (formerly X4 Pharmaceuticals, Inc.) ("X4") on March 13, 2019 (the "Merger"). F1 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to the option vested on October 4, 2019, and one thirty-sixth (1/36th) of the shares subject to the option shall vest each month thereafter, subject to the Reporting Person continuing to provide service through each such date. Read SEC document |
| May 07, 2018 Filed May 9, 2018 22:15 UTC | Neurogene Inc. AQXP · Entity 5160 | GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $13.10 | $0.00 |
DisclosureSEC source: 0001209191-18-028979 · doc4.xml · derivative · entry 1 Bridger Gary · CIK 0001600049 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2028-05-06 F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable at a rate of 1/12th of the total number of shares underlying the options on the one-month anniversary of May 7, 2018 (the "Vesting Commencement Date") and 1/12th of the total number of shares underlying the options each monthly anniversary of the Vesting Commencement Date thereafter for so long as the recipient of the option provides continuous service to the issuer, such that the total number of shares underlying the options shall be fully vested on the one-year anniversary of the Vesting Commencement Date. Read SEC document |
| May 08, 2017 Filed May 10, 2017 22:29 UTC | Neurogene Inc. AQXP · Entity 5160 | GrantStock Option (Right to Buy) · Derivative | 9,000 | $0.00 Strike: $13.74 | $0.00 |
DisclosureSEC source: 0001209191-17-031395 · doc4.xml · derivative · entry 1 Bridger Gary · CIK 0001600049 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 Underlying: Common Stock · 9,000 shares Expires 2027-05-07 F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable at a rate of 1/12th of the total number of shares underlying the options on the one-month anniversary of May 8, 2017 (the "Vesting Commencement Date") and 1/12th of the total number of shares underlying the options each monthly anniversary of the Vesting Commencement Date thereafter for so long as the recipient of the option provides continuous service to the issuer, such that the total number of shares underlying the options shall be fully vested on the one-year anniversary of the Vesting Commencement Date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.